Camrelizumab and apatinib in Chinese patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer: an exploratory open-label, single-arm trial
Xin Zhang, Di Sun, Yingqiang Zhang, Zhuanzhuan Mu, Cong Shi, Yuqing Sun, Xinqi Cheng, Chao Meng, Xing Wei, Jun Liang, Yansong Lin · 2025
Read Camrelizumab and apatinib in Chinese patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer: an exploratory open-label, single-arm trial by Xin Zhang, Di Sun, Yingqiang Zhang, Zhuanzhuan Mu, Cong Shi, Yuqing Sun, Xinqi Cheng, Chao Meng, Xing Wei, Jun Liang, Yansong Lin (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12828957.txt.
Description
Xin Zhang and co-authors trialled two drugs together in Chinese patients with hard-to-treat thyroid cancer in a 2025 study. Their cancer no longer responded to radioactive iodine, a standard therapy. An immune drug plus a vessel-blocking drug had shown synergy in other tumours, but data here were limited.
Twenty patients received the pair in cycles until disease progressed or side effects grew too strong. Median time without progress was eleven months, in both first-line and later use. Three in ten patients had tumours shrink in part, and almost all had disease controlled. Liver enzyme rises were the most common severe side effects. The authors back further study of the pair.
Catalog record
| CREATOR | Xin Zhang, Di Sun, Yingqiang Zhang, Zhuanzhuan Mu, Cong Shi, Yuqing Sun, Xinqi Cheng, Chao Meng, Xing Wei, Jun Liang, Yansong Lin |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |